Skip to content
November 14, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Medical Research and Clinical Trials
  • Landmark Cambridge Study Reveals Bilateral Salpingo-Oophorectomy Dramatically Improves Survival for BRCA1 and BRCA2 Breast Cancer Patients
  • Medical Research and Clinical Trials

Landmark Cambridge Study Reveals Bilateral Salpingo-Oophorectomy Dramatically Improves Survival for BRCA1 and BRCA2 Breast Cancer Patients

Ammar Sabilarrohman November 14, 2026 16 minutes read
landmark-cambridge-study-reveals-bilateral-salpingo-oophorectomy-dramatically-improves-survival-for-brca1-and-brca2-breast-cancer-patients

Cambridge, UK – [Insert Date] – A groundbreaking study from the University of Cambridge has delivered critical news for women diagnosed with breast cancer who carry specific BRCA1 and BRCA2 genetic variants. The research, published today in the prestigious journal The Lancet Oncology, demonstrates that bilateral salpingo-oophorectomy (BSO) – the surgical removal of the ovaries and fallopian tubes – is associated with a substantial reduction in the risk of early death among these high-risk individuals, without incurring serious long-term side-effects. This finding provides crucial evidence to support a procedure previously recommended primarily for ovarian cancer prevention, now showing profound benefits for overall survival.

Main Facts

The study, a first-of-its-kind large-scale investigation, provides compelling evidence that BSO not only significantly reduces the risk of ovarian cancer but also drastically improves the overall survival rates for women with a history of breast cancer who carry pathogenic variants in the BRCA1 and BRCA2 genes. This comes as a significant reassurance for patients and clinicians, addressing long-standing concerns about the potential adverse consequences of surgically induced early menopause.

A Landmark Study from Cambridge

For decades, women with inherited mutations in the BRCA1 and BRCA2 genes have faced a difficult choice: to undergo prophylactic surgery to mitigate their heightened cancer risks, or to live with the anxiety of a substantially increased likelihood of developing aggressive cancers. While the preventive power of BSO against ovarian cancer was well-established, its broader impact on overall survival, particularly for those already diagnosed with breast cancer, remained a critical unanswered question.

The Cambridge team, leveraging an innovative methodology to circumvent ethical barriers inherent in traditional clinical trials, has now provided definitive answers. Their analysis of extensive NHS electronic health records and genetic testing data has revealed a clear and compelling picture of BSO’s profound benefits.

The Lifesaving Impact of BSO

The core finding of the study is stark: women carrying BRCA1 and BRCA2 variants who had undergone BSO were approximately half as likely to die from cancer or any other cause during the median 5.5-year follow-up period. This translates to a significantly extended lifespan and reduced mortality risk for a highly vulnerable patient population.

Specifically, the reduction in mortality was more pronounced in BRCA2 carriers, who experienced a 56% lower risk of early death compared to BRCA1 carriers, who saw a 38% reduction. Beyond extending life, the procedure also conferred a roughly 40% lower risk of developing a second primary cancer, further cementing its role as a multifaceted protective intervention. These findings underscore the critical importance of BSO not just as an ovarian cancer preventative, but as a comprehensive strategy to improve long-term outcomes for these high-risk women.

Addressing Long-Standing Concerns

A major concern surrounding BSO has always been the sudden onset of menopause it induces. The removal of ovaries, the body’s primary source of oestrogen, can trigger a cascade of symptoms including hot flashes, mood swings, bone density loss, and potentially increased risks of cardiovascular disease and cognitive decline. For breast cancer survivors, who often cannot receive hormone replacement therapy (HRT) due to concerns about stimulating cancer recurrence, these potential side effects are particularly daunting.

Crucially, the Cambridge study found no link between BSO and an increased risk of long-term adverse health outcomes such as heart disease, stroke, or depression. This finding directly contradicts some previous studies in the general population that suggested an association between surgical menopause and these conditions. For BRCA1 and BRCA2 carriers with a history of breast cancer, this reassurance regarding the absence of serious long-term side effects is invaluable, allowing for more confident decision-making regarding this life-altering surgery.

Chronology

The journey to understanding the intricate relationship between genetic predisposition, prophylactic surgery, and long-term survival for BRCA carriers has been a progressive one, marked by scientific discovery, clinical recommendations, and persistent unanswered questions.

The Genetic Predisposition: Understanding BRCA1 and BRCA2

The story begins with the identification of the BRCA1 and BRCA2 genes in the mid-1990s. These genes are pivotal tumor suppressor genes, playing a crucial role in DNA repair. When these genes carry pathogenic variants (mutations), their ability to repair damaged DNA is compromised, significantly increasing an individual’s lifetime risk of developing certain cancers, most notably breast and ovarian cancer.

For women with a BRCA1 pathogenic variant, the lifetime risk of developing breast cancer can be as high as 72%, and the risk of ovarian cancer can reach 44%. For BRCA2 carriers, the lifetime breast cancer risk is similarly elevated, around 69%, with an ovarian cancer risk of about 17%. These figures are starkly higher than those in the general population, prompting intense research into effective risk-reduction strategies. The aggressive nature and often late-stage diagnosis of ovarian cancer, in particular, made prevention a paramount concern.

The Surgical Intervention: Bilateral Salpingo-Oophorectomy (BSO)

Given the high genetic risk, medical guidelines evolved to recommend prophylactic bilateral salpingo-oophorectomy (BSO) for women with BRCA1 and BRCA2 variants. This surgical procedure involves the removal of both ovaries and fallopian tubes. The rationale was clear: by removing the organs most susceptible to developing cancer, the risk could be dramatically reduced. Previous studies had already demonstrated that BSO could lead to an impressive 80% reduction in the risk of developing ovarian cancer among these women.

The recommended age for BSO varies slightly depending on the specific gene variant, reflecting the different age-related penetrance of cancer risk: typically between ages 35 and 40 for BRCA1 carriers, and between ages 40 and 45 for BRCA2 carriers. These age ranges are chosen to balance the desire for risk reduction with the desire to preserve fertility and natural hormone production for as long as safely possible.

The Unanswered Questions: Early Menopause and Risks

Despite the clear benefits in ovarian cancer prevention, the widespread adoption of BSO was accompanied by legitimate concerns. The procedure induces immediate surgical menopause, which can have profound and immediate effects on a woman’s body and quality of life. The sudden cessation of ovarian hormone production can lead to a host of menopausal symptoms, including hot flashes, night sweats, vaginal dryness, sleep disturbances, and mood changes.

Beyond these immediate symptoms, there were also theoretical and observed long-term risks associated with early menopause in the general population. These included increased risks of cardiovascular disease, osteoporosis, cognitive decline, and depression. For breast cancer survivors, these concerns were amplified, as many are advised against or unable to take hormone replacement therapy (HRT) to mitigate menopausal symptoms, given the potential for HRT to stimulate hormone-sensitive breast cancer cells. This left a critical gap in knowledge: while BSO prevented ovarian cancer, what was its overall impact on the health and survival of women already battling or having survived breast cancer, particularly in the absence of HRT? This complex interplay of benefits and risks necessitated further investigation, which the Cambridge study has now provided.

Supporting Data

The groundbreaking nature of the Cambridge study lies not only in its significant findings but also in its innovative methodological approach, which allowed researchers to overcome formidable ethical and practical challenges.

Navigating Ethical Hurdles: The Power of Real-World Data

Traditionally, the "gold standard" for evaluating the efficacy and safety of medical interventions is a randomised controlled trial (RCT). In an RCT, participants are randomly assigned to either receive the intervention (e.g., BSO) or a control (e.g., no BSO), allowing researchers to isolate the effects of the treatment with high confidence. However, conducting an RCT for BSO in women carrying BRCA1 and BRCA2 pathogenic variants would be profoundly unethical. Randomly assigning a group of women known to be at extremely high risk of a deadly cancer to a "no surgery" control arm would knowingly place them at substantially greater risk of developing ovarian cancer, a morally untenable position.

To circumvent this ethical dilemma, the Cambridge team, in collaboration with the National Disease Registration Service (NDRS) in NHS England, pioneered an approach using vast electronic health records and data from NHS genetic testing laboratories. This "real-world evidence" approach allowed them to compare outcomes between women who opted for BSO and those who did not, all within a naturalistic clinical setting. This methodology, while not a true RCT, provided a robust and comprehensive dataset large enough to draw statistically powerful conclusions about long-term outcomes. This innovative use of existing health data sets a precedent for future research in areas where traditional RCTs are impractical or unethical.

Study Design and Cohort

The study meticulously identified a substantial cohort of 3,400 women who carried either a BRCA1 or BRCA2 cancer-causing variant and had also been diagnosed with breast cancer. This cohort was evenly split, with approximately 1,700 women for each variant. Within this group, a significant proportion had undergone BSO: around 850 of the BRCA1 carriers and 1,000 of the BRCA2 carriers had chosen to have the surgery.

The researchers then followed these women over a median period of 5.5 years, carefully tracking various health outcomes, including overall mortality, incidence of secondary cancers, and the development of specific long-term conditions such as heart disease, stroke, and depression. The large sample size and the comprehensive nature of the NHS data allowed for a powerful statistical analysis, enabling the team to adjust for potential confounding factors and draw reliable conclusions.

Unpacking the Survival Benefits

The results were compelling and statistically significant. Women who underwent BSO experienced a dramatic reduction in their risk of early death from any cause. This reduction was approximately 50% across the entire cohort. When broken down by gene variant, the benefits were even clearer:

  • BRCA2 carriers: Showed a remarkable 56% reduction in early death risk. This suggests a particularly strong protective effect of BSO in this group, potentially due to the specific biological pathways affected by the BRCA2 gene and its interaction with ovarian hormones.
  • BRCA1 carriers: Experienced a substantial 38% reduction in early death risk. While slightly less pronounced than in BRCA2 carriers, this is still a highly significant and clinically meaningful improvement in survival.

Furthermore, the study revealed another critical benefit: a roughly 40% lower risk of developing a second primary cancer. This finding is particularly important for breast cancer survivors, who remain at elevated risk for new cancers, including contralateral breast cancer and other BRCA-associated malignancies, even after their initial diagnosis and treatment. The systemic effects of hormone removal, or the prevention of ovarian cancer itself, likely contribute to this broad protective effect against secondary malignancies.

Dispelling Fears: No Increased Risk of Other Conditions

One of the most reassuring findings of the study was the absence of any increased risk of other long-term health outcomes commonly associated with early menopause. The researchers found no link between BSO and an elevated risk of heart disease, stroke, or depression. This stands in stark contrast to some previous observational studies in the general population, which have suggested a correlation between surgical menopause and these conditions.

The disparity in findings could be attributed to several factors. The BRCA-positive population might have unique physiological characteristics, or the intense medical surveillance and counselling associated with their high-risk status might play a protective role. Regardless of the exact mechanism, this finding provides crucial reassurance, allowing women and their clinicians to focus on the overwhelming survival benefits of BSO without the burden of concern for these specific adverse long-term effects. The absence of these commonly feared complications significantly strengthens the risk-benefit profile of BSO for this specific patient group.

Official Responses

The publication of these findings has elicited strong responses from the research team, highlighting both the clinical significance of the results and the broader implications for healthcare policy and research methodology.

Expert Perspectives on the Findings

Hend Hassan, the first author of the study and a PhD student at the Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, and Wolfson College, Cambridge, articulated the immediate relief these findings offer. "We know that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer, but there’s been a question mark over the potential unintended consequences that might arise from the sudden onset of menopause that this causes," Hassan stated. "Reassuringly, our research has shown that for women with a personal history of breast cancer, this procedure brings clear benefits in terms of survival and a lower risk of other cancers without the adverse side effects such as heart conditions or depression." Her words underscore the direct impact these findings will have on patient counselling and peace of mind.

Professor Antonis Antoniou, from the Department of Public Health and Primary Care and the study’s senior author, emphasized the practical utility of the research. "Our findings will be crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation," he noted. This highlights the immediate translation of research into clinical practice, empowering patients with robust evidence to guide their personal health choices.

The Call to Action: Addressing Disparities

While the benefits of BSO are now clearer than ever, the study also uncovered concerning disparities in its uptake. The research revealed that most women undergoing BSO in the study cohort were white. Black and Asian women were approximately half as likely to have BSO compared to white women. Furthermore, women residing in less deprived areas were more likely to undergo the procedure compared to those in the most-deprived category.

These disparities prompted a strong call to action from Hend Hassan. "Given the clear benefits that this procedure provides for at-risk women, it’s concerning that some groups of women are less likely to undergo it," she remarked. "We need to understand why this is and encourage uptake among these women." This statement highlights a critical public health challenge: ensuring equitable access to life-saving interventions across all demographic and socio-economic groups. Potential factors contributing to these disparities could include differences in genetic testing rates, access to specialized care, cultural perceptions of prophylactic surgery, communication barriers, and socio-economic constraints that impact healthcare navigation. Addressing these systemic issues will be crucial to maximize the public health benefit of BSO.

A Testament to NHS Data

Professor Antoniou also took the opportunity to commend the infrastructure that made this research possible. As Director of the Cancer Data-Driven Detection programme, he added, "The study also highlights the power of exceptional NHS datasets in driving impactful, clinically relevant research." This recognition underscores the immense value of comprehensive, well-maintained electronic health records and genetic testing databases within national healthcare systems. Such rich datasets, when utilized ethically and effectively, can provide unparalleled insights into long-term health outcomes and inform clinical guidelines in ways that traditional research methods cannot. The NHS data, curated by the National Disease Registration Service (NDRS), serves as a powerful resource for advancing medical knowledge and improving patient care on a national scale.

Implications

The findings of this Cambridge study carry profound implications, poised to reshape clinical guidelines, empower patient decision-making, and influence the future trajectory of medical research and healthcare equity.

Reshaping Patient Counselling and Clinical Guidelines

The most immediate and significant implication of this study is its direct impact on genetic counselling and clinical guidelines for women with BRCA1 and BRCA2 pathogenic variants who have a history of breast cancer. Previously, while BSO was strongly recommended for ovarian cancer prevention, the nuanced discussion around overall survival and potential long-term side effects was often fraught with uncertainty. Now, clinicians can counsel their patients with greater confidence, presenting BSO not just as an ovarian cancer preventative, but as a robust intervention that significantly reduces overall mortality and the risk of secondary cancers, without introducing new cardiovascular or mental health risks.

This newfound clarity will empower women to make more informed decisions about their healthcare. For many, the reassurance that BSO offers a substantial survival advantage without serious long-term adverse effects will likely increase their willingness to consider the procedure. This could lead to a significant increase in uptake among eligible women, ultimately saving lives. Medical societies and guideline development bodies are expected to swiftly incorporate these findings into their recommendations, solidifying BSO’s critical role in comprehensive cancer risk management for this high-risk population.

Paving the Way for Data-Driven Research

The methodology employed by the Cambridge team – leveraging extensive real-world data from NHS electronic health records and genetic testing laboratories – sets a powerful precedent for future medical research. In situations where traditional randomised controlled trials are ethically or practically unfeasible, large-scale observational studies using high-quality, routinely collected data can provide invaluable insights. This approach offers a cost-effective and efficient way to address critical clinical questions, particularly for rare conditions or interventions with long-term outcomes that are difficult to track in conventional trials.

The success of this study underscores the immense potential of national health datasets to drive impactful, clinically relevant research. It highlights the importance of investing in robust data infrastructure, ensuring data quality, and developing advanced analytical techniques to extract meaningful information. This paradigm shift towards data-driven discovery could accelerate the pace of medical advancements and improve patient outcomes across a wide spectrum of diseases.

The Road Ahead: Ensuring Equitable Access

The observed disparities in BSO uptake among different ethnic groups and socio-economic strata represent a significant public health challenge that demands urgent attention. The "clear benefits" of BSO articulated by the researchers must be accessible to all eligible women, regardless of their background or location. Future efforts must focus on understanding the root causes of these disparities. This could involve:

  • Improving genetic testing access and awareness: Ensuring that all women at risk, particularly those from underserved communities, are offered and encouraged to undergo genetic testing.
  • Enhancing patient education and counselling: Developing culturally sensitive educational materials and training healthcare providers to communicate complex genetic information and surgical options effectively to diverse populations.
  • Addressing systemic barriers: Investigating and mitigating socio-economic factors, language barriers, transportation issues, and healthcare navigation challenges that may impede access to specialized surgical care.
  • Community engagement: Collaborating with community leaders and advocacy groups to build trust and disseminate vital health information.

Only by actively addressing these inequities can the full life-saving potential of BSO be realized across the entire population of high-risk women.

The Future of Cancer Research at Cambridge

The research was generously funded by Cancer Research UK, with additional support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, underscoring the collaborative effort and significant investment in cutting-edge cancer research within the UK.

Looking forward, the University of Cambridge and Addenbrooke’s Charitable Trust (ACT) are actively fundraising for a new, state-of-the-art Cambridge Cancer Research Hospital. This ambitious project, a partnership with Cambridge University Hospitals NHS Foundation Trust, aims to transform cancer diagnosis and treatment. While the hospital will serve patients across the East of England, the research conducted within its walls promises to have a far-reaching impact, changing the lives of cancer patients not only across the UK but globally. This study serves as a testament to the calibre of research that will continue to emanate from Cambridge, driving progress in the fight against cancer.

About the Author

Ammar Sabilarrohman

Author

View All Posts

Post navigation

Previous: AHA26: CRISPR gene editing shows promise in Phase Ib hypertriglyceridaemia trial

Related Stories

aha26-crispr-gene-editing-shows-promise-in-phase-ib-hypertriglyceridaemia-trial
  • Medical Research and Clinical Trials

AHA26: CRISPR gene editing shows promise in Phase Ib hypertriglyceridaemia trial

Reynand Wu November 14, 2026
salk-scientists-uncover-estrogen-related-receptors-as-a-master-key-to-revitalize-metabolism-and-combat-muscle-fatigue
  • Medical Research and Clinical Trials

Salk Scientists Uncover Estrogen-Related Receptors as a Master Key to Revitalize Metabolism and Combat Muscle Fatigue

Pevita Pearce November 14, 2026
aha-2026-novo-reveals-baseline-data-for-phase-iii-artemis-trial
  • Medical Research and Clinical Trials

AHA 2026: Novo reveals baseline data for Phase III ARTEMIS trial

Dwi Wanna November 14, 2026

Recent Posts

  • Landmark Cambridge Study Reveals Bilateral Salpingo-Oophorectomy Dramatically Improves Survival for BRCA1 and BRCA2 Breast Cancer Patients
  • AHA26: CRISPR gene editing shows promise in Phase Ib hypertriglyceridaemia trial
  • Voices of Experience: Breast Cancer Survivors Share Wisdom for Those Facing Diagnosis and Treatment
  • Advancing the Frontier of Precision Oncology: Breakthroughs in Breast Cancer Treatment from ESMO 2024
  • The New Era of Precision Oncology: How Breast Cancer Canada is Revolutionizing Patient Outcomes Through Research and Digital Innovation

Recent Comments

No comments to show.

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

landmark-cambridge-study-reveals-bilateral-salpingo-oophorectomy-dramatically-improves-survival-for-brca1-and-brca2-breast-cancer-patients
  • Medical Research and Clinical Trials

Landmark Cambridge Study Reveals Bilateral Salpingo-Oophorectomy Dramatically Improves Survival for BRCA1 and BRCA2 Breast Cancer Patients

Ammar Sabilarrohman November 14, 2026
aha26-crispr-gene-editing-shows-promise-in-phase-ib-hypertriglyceridaemia-trial
  • Medical Research and Clinical Trials

AHA26: CRISPR gene editing shows promise in Phase Ib hypertriglyceridaemia trial

Reynand Wu November 14, 2026
voices-of-experience-breast-cancer-survivors-share-wisdom-for-those-facing-diagnosis-and-treatment
  • Patient Advocacy and Support

Voices of Experience: Breast Cancer Survivors Share Wisdom for Those Facing Diagnosis and Treatment

Dwi Wanna November 14, 2026
Scientists working with samples in laboratory
  • Patient Advocacy and Support

Advancing the Frontier of Precision Oncology: Breakthroughs in Breast Cancer Treatment from ESMO 2024

Laily UPN November 14, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.